ET-190 / Eureka Therap - LARVOL DELTA

A novel anti-CD19 chimeric T cell therapy platform ET019002 was safe and effective in inducing CR in blast crisis of CML: A case study. (ASCO 2019) - P1; "Repeated infusion of autologous ET019002 was safe and achieved a three-month CR after the ET019002 T cells therapy, which could provide a window for the patient to receive curative therapies such as bridging allogeneic hematopoietic stem cells. Clinical trial information: NCT03642496"

Clinical • IO Biomarker

First-in-Human Study of ET019003, a Next Generation Anti-CD19 T-Cell Therapy, in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL) (ASH 2019) - "Following a 3-day preconditioning treatment with Fludarabine (25mg/m2/day)/ Cyclophosphamide (250mg/m2/day), patients received i.v. infusions of ET019003 T cells at an initial dose of 2-3×106 cells/kg. Preliminary results from six CD19+ r/r DLBCL patients in a FIH study show that ET019003 T-cell therapy is safe with robust in vivo T-cell expansion. The clinical study is on-going and we are monitoring safety as well as duration of response in longer follow-up. Reference: Xu et al."

Clinical • IO biomarker • P1 data • CNS Disorders • Diffuse Large B Cell Lymphoma • Epilepsy • Hematological Disorders • Hematological Malignancies • Herpes Zoster • Immune Modulation • Inflammation • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Thrombocytopenia • Varicella Zoster

Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma (clinicaltrials.gov) - P1; N=4; Completed; Sponsor: Eureka Therapeutics Inc.; Active, not recruiting ➔ Completed; N=21 ➔ 4; Trial completion date: Jun 2021 ➔ Dec 2020; Trial primary completion date: Jun 2021 ➔ Dec 2020

Clinical • Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • CD19

Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma (clinicaltrials.gov) - P1; N=21; Active, not recruiting; Sponsor: Eureka Therapeutics Inc.; Trial completion date: Jun 2020 ➔ Jun 2021; Trial primary completion date: Jun 2020 ➔ Jun 2021

Clinical • Trial completion date • Trial primary completion date • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • CD19

Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma (clinicaltrials.gov) - P1; N=21; Active, not recruiting; Sponsor: Eureka Therapeutics Inc.; Recruiting ➔ Active, not recruiting; Trial completion date: Sep 2019 ➔ Jun 2020; Trial primary completion date: Sep 2019 ➔ Jun 2020

Clinical • Enrollment closed • Trial completion date • Trial primary completion date

Safety and Efficiency Study of ET019003-T Cells in Relapsed, Refractory CD19+ B Cell Leukemia and Lymphoma (clinicaltrials.gov) - P1; N=50; Recruiting; Sponsor: Wuhan Union Hospital, China

Clinical • New P1 trial

ET190L1-ARTEMIS™ T Cells in Relapsed, Refractory B Cell Leukemia and Lymphoma (clinicaltrials.gov) - P1; N=18; Recruiting; Sponsor: First Affiliated Hospital Xi'an Jiaotong University

Clinical • New P1 trial